WENDY'S LMS JOURNEY
Understanding Leiomyosarcoma (LMS)
Leiomyosarcoma (LMS) is a rare and aggressive cancer that develops in the smooth muscle tissues of the body. As a type of soft tissue sarcoma, it primarily spreads through the bloodstream, making it capable of affecting any soft tissue. Due to its rarity, LMS is often challenging to diagnose and treat effectively. The exact cause of LMS remains unknown, and ongoing research aims to uncover potential risk factors and targeted treatments.
Treatment Options for LMS
Given the aggressive nature of LMS, treatment options vary depending on the tumor’s size, location, and spread. Unfortunately, traditional chemotherapy and radiation have shown limited success in treating LMS. The most effective treatment approach currently available is surgical removal of tumors. Some of the treatment options include:
Surgery: The primary treatment for LMS, often requiring the removal of affected organs or tissues to achieve clear margins and prevent recurrence.
Targeted Therapy: Research is ongoing to develop targeted drugs that attack cancer cells while sparing healthy tissue.
Clinical Trials: Many patients explore clinical trials in the hopes of accessing cutting-edge treatments and potential breakthroughs.
Palliative Care: For advanced cases, symptom management and pain relief play a crucial role in improving quality of life.
Wendy’s LMS Journey
Wendy’s journey with LMS began in October 2024, when she discovered a large mass on the right side of her abdomen. After undergoing a CT scan and MRI, the results revealed three tumors: the largest in her right retroperitoneum, a second in her small bowel, and a third in her left hip muscle. She was hospitalized for three weeks, during which additional tests and a biopsy confirmed the diagnosis of stage 4 metastatic leiomyosarcoma.
Thankfully, Wendy’s surgical team successfully removed all three tumors, though her right kidney had to be removed in the process. Despite this, her battle with LMS continues, as two new tumors have since developed. Given the limited effectiveness of chemotherapy and radiation, surgery remains the best treatment option for Wendy. She remains hopeful and determined, drawing strength from her loved ones and the LMS community. We continue to stand by her side, hoping for medical advancements that bring us closer to a cure.
While LMS is a formidable adversary, continued research, awareness, and support offer hope for those affected. Wendy’s story is a testament to resilience, and together, we strive for progress in the fight against leiomyosarcoma.
